Streetbeat News

Revenues

ABVC

ABVC BioPharma, Inc. (NASDAQ:ABVC) is advancing in the oncology and hematology fields with its development of combination therapy for cancer treatment and immunity booster dietary supplements, both derived from Maitake Mushroom. The company has initiated marketing and sales of these dietary supplements in the US, Canada, and Asia, and expects revenue generation through its CDMO subsidiary, BioKey, Inc. The US FDA has approved four INDs for various cancer treatments. ABVC is set to begin Phase II clinical trials to study the efficacy and safety of its drug formulation as a combination therapy for oncology. The company's R&D efforts have been recognized with FDA approvals, and it is working on co-development projects with Rgene Corporation. The global markets for cancer therapeutics, dietary supplements, pharmaceutical CDMO, and botanical drugs are projected to grow significantly by 2032.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:45 pm

PNW

Pinnacle West Capital (PNW) reported Q4 earnings per share (EPS) of $0.00, an improvement over the estimated $(0.13), but missed sales estimates with $991.57M against the expected $1.12B, marking an 11.47% miss and a 1.76% decrease from last year's $1.01B.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:38 pm

SYNX

Silynxcom has received a repeat order worth $280,000 from a military customer, indicating continued trust and satisfaction with their products. This order could signal strong ongoing relationships and potential for future orders, positively impacting Silynxcom's financial performance.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:34 pm

EVER

EverQuote, Inc. (NASDAQ:EVER) shares surged premarket Tuesday after reporting Q4 FY23 results that exceeded expectations and providing strong guidance. Despite a 37% Y/Y revenue decline to $55.71 million, it beat the $49.81 million consensus. Automotive insurance revenue fell 33% to $45.0 million, while home and renters insurance revenue increased 48% Y/Y to $9.8 million. The company achieved a Variable Marketing Margin of 37% of revenue, improved from 33% the previous year, and reported an adjusted EBITDA loss of $(0.9) million, better than expected. EverQuote anticipates Q1 2024 revenue between $78.0 million and $82.0 million, significantly above the $65.13 million consensus.

Portfolio Pulse from Lekha Gupta

February 27, 2024 | 1:21 pm

CPRX

Catalyst Pharmaceuticals announced its participation in the 2024 MDA Clinical & Scientific Conference, presenting a poster on a registry for studying the long-term safety and quality of life in Duchenne muscular dystrophy patients treated with AGAMREE (vamorolone). The registry aims to track the progress of 250 male patients across 25 U.S. sites, with the first interim analysis expected in May 2025. AGAMREE, a novel corticosteroid with a unique mode of action, has shown promise in the VISION-DMD study and received U.S. FDA approval on October 26, 2023, with Orphan Drug and Rare Pediatric Disease designation.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:17 pm

LTBR

Lightbridge CEO Seth Grae provided an update to shareholders, highlighting 2023 achievements and future milestones. Key developments include strengthening the leadership team, agreements with Centrus Energy for a pilot fuel fabrication facility in Ohio, and an engineering study for CANDU reactors with RATEN ICN. Lightbridge also announced a research study with Texas A&M University, NuScale Power, and Structural Integrity Associates, and a significant finding on plutonium disposition. The company is adopting the Technology Readiness Level (TRL) system, currently at TRL 4-5, indicating progress towards commercialization. Upcoming milestones include expanding the fuel development team, ongoing work at Idaho National Laboratory, completing the CANDU reactor study, the FEED study with Centrus, and commencing manufacturing efforts for irradiation testing. COP28 recognized nuclear energy's role in decarbonization, with a commitment to triple nuclear capacity by 2050, highlighting the demand for Lightbridge's nuclear fuel technology.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:13 pm

GLD

SPY

USO

U.S. stock markets closed lower on Monday, with the S&P 500, Dow Jones, and Nasdaq all experiencing declines amid a focus on upcoming economic indicators. Asian and European markets, however, saw gains in various sectors. Crude oil prices slightly decreased, while gold and other commodities rose. U.S. futures indicated a positive opening for the next trading day. Economic data showed a drop in U.S. building permits but an increase in new single-family home sales.

Portfolio Pulse from Akanksha Bakshi

February 27, 2024 | 1:13 pm

PTLO

Portillo's has outlined its long-term growth expectations, projecting restaurant unit growth of 12% to 15%, total revenue growth in the mid-teens, and adjusted EBITDA growth in the low teens.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:06 pm

IMXI

IntL Money Express (IMXI) provided guidance for Q1 and FY24, forecasting revenues and EPS below analyst estimates. For Q1, revenue is expected between $150.4M-$155.0M with adjusted EPS of $0.39-$0.42. For FY24, revenue projections are $681.0M-$701.8M with adjusted EPS of $2.13-$2.31.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:05 pm

PTLO

Portillo's has announced plans to open at least nine new restaurants in FY24, with commodity inflation expected to range from 4% to 6%. For 2025, the company targets at least 12% new restaurant growth, with a long-term outlook of approximately 12% to 15% annual new restaurant growth.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:05 pm